Biotech · Private company · Atlanta, GA, US

MapHabit, Inc.

Track this companyFree. Adds MapHabit, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials

Pipeline4

Clinical trials4

NIH awards6

  • Adding technology that will enhance commercialization of our neuroscience-based innovative assistive technology platform for living with Alzheimer's disease and Alzheimer's disease related dementiaFiscal year 2026 · $1.2MNIH RePORTER 5SB1AG087924-03 · fetched Nov 12, 2026
  • Adding technology that will enhance commercialization of our neuroscience-based innovative assistive technology platform for living with Alzheimer's disease and Alzheimer's disease related dementiaFiscal year 2025 · $1.4MNIH RePORTER 5SB1AG087924-02 · fetched Nov 12, 2026
  • Adding technology that will enhance commercialization of our neuroscience-based innovative assistive technology platform for living with Alzheimer's disease and Alzheimer's disease related dementiaFiscal year 2024 · $1.2MNIH RePORTER 1SB1AG087924-01 · fetched Nov 12, 2026
  • An assistive-technology based Caregiver Training Program (CTP) to enhance caregiver effectiveness, well-being, and quality of life, which will improve overall care for individuals living with AD/ADRD.Fiscal year 2024 · $45.4KNIH RePORTER 3R44AG076256-02S1 · fetched Nov 12, 2026
  • An assistive-technology based Caregiver Training Program (CTP) to enhance caregiver effectiveness, well-being, and quality of life, which will improve overall care for individuals living with AD/ADRD.Fiscal year 2024 · $88.1KNIH RePORTER 3R44AG076256-03S1 · fetched Nov 12, 2026
  • An assistive-technology based Caregiver Training Program (CTP) to enhance caregiver effectiveness, well-being, and quality of life, which will improve overall care for individuals living with AD/ADRD.Fiscal year 2024 · $1.2MNIH RePORTER 5R44AG076256-03 · fetched Nov 12, 2026